The world is facing a dire need for new antibiotics and vaccines, with drug-resistant infections claiming nearly 5 million lives annually. The pharmaceutical industry's retreat from antibiotic development has left a gaping hole in our ability to combat these deadly pathogens. But there's a glimmer of hope on the horizon: Basecamp Research's groundbreaking EDEN models, now integrated with Claude Science, are revolutionizing the way we design antibiotics and predict vaccine targets.
A Race Against Time
Developing antibiotics and vaccines is a race against time, especially in the face of rapidly evolving drug-resistant pathogens. Traditionally, identifying vaccine targets required months of empirical laboratory work, a delay that often costs lives. But with the integration of EDEN models into Claude Science, researchers can now achieve the same result in a matter of minutes.
The Power of EDEN
EDEN, built on the world's largest biological dataset, BaseData, is a powerful tool that has been trained on the most diverse and least understood life forms on Earth. This diversity is key to its success, as it allows EDEN to outperform other genomic foundation models in vaccine design. By describing a problem in plain language, researchers can have Claude run a prioritization workflow against a pathogen's genetic sequence, significantly reducing the time and effort required for vaccine development.
Antibiotic Design: A Game-Changer
In collaboration with the University of Pennsylvania, Basecamp Research demonstrated the incredible capabilities of EDEN in antibiotic design. 97% of the antibiotic peptides designed by EDEN were found to be active against World Health Organization (WHO) priority pathogens when tested in the lab. One standout candidate, EDEN-7, showed remarkable efficacy against multidrug-resistant Acinetobacter baumannii, a pathogen associated with hospital outbreaks worldwide, despite being generated zero-shot.
A Collaboration for the Ages
The collaboration between Basecamp Research and the University of Pennsylvania highlights the potential of frontier biological foundation models paired with rigorous experimental validation. By making EDEN available through Claude Science, researchers can accelerate antibiotic discovery and address the antibiotic crisis head-on. This partnership is a testament to the power of collaboration between academia and industry in tackling some of the greatest existential threats facing humanity.
Looking Ahead
The integration of EDEN models with Claude Science is a significant step forward in the fight against drug-resistant infections. As Basecamp Research continues to scale BaseData through the Trillion Gene Atlas, the potential for AI-driven drug discovery becomes even more promising. With EDEN's ability to design potent antibiotics and predict vaccine targets, we may be on the cusp of a new era in healthcare, where the threat of antibiotic resistance is mitigated, and the race against time is won.
